Imaging the distribution of polymyxins in the kidney

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 3, 2015, Pages 827-829

  Yun, Bo ^a   Azad, Mohammad A K ^a   Wang, Jiping ^a   Nation, Roger L ^a   Thompson, Philip E ^a   Roberts, Kade D ^a   Velkov, Tony ^a   Li, Jian ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Mice; Nephrotoxicity; Polymyxin B

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN M ANTIBODY; POLYMYXIN B; ANTIINFECTIVE AGENT; POLYMYXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DRUG ACCUMULATION; DRUG TISSUE LEVEL; FLUOROSCOPY; IMAGING; IMMUNOHISTOCHEMISTRY; KIDNEY CORTEX; KIDNEY PARENCHYMA; KIDNEY TUBULE ABSORPTION; MOUSE; NEPHROTOXICITY; NONHUMAN; TISSUE SECTION; ANIMAL; CHEMICALLY INDUCED; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; FEMALE; FLUORESCENCE MICROSCOPY; KIDNEY; KIDNEY FAILURE; PATHOLOGY;

ANIMALS; ANTI-BACTERIAL AGENTS; DISEASE MODELS, ANIMAL; FEMALE; KIDNEY; MICE; MICROSCOPY, FLUORESCENCE; POLYMYXINS; RENAL INSUFFICIENCY;

EID: 84928188529     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku441     Document Type: Article

References (16)

1. Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1-12.
2. Boucher HW, Talbot GH, Benjamin DK Jr et al. 10×'20 Progress-development of new drugs active against Gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 2013; 56:1685-94.
3. Velkov T, Roberts KD, Nation RL et al. Pharmacology of polymyxins: new insights into an 'old' class of antibiotics. Future Microbiol 2013; 8:711-24.
4. Kubin CJ, Ellman TM, Phadke V et al. Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy. J Infect 2012; 65:80-7.
5. Sandri AM, Landersdorfer CB, Jacob J et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis 2013; 57:524-31.
6. Abdelraouf K, Braggs KH, Yin T et al. Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design. Antimicrob Agents Chemother 2012; 56:4625-9.
7. Li J. Mechanism of polymyxin-induced nephrotoxicity. In: Abstracts of the Fifty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, USA, 2014. Abstract A-1131. American Society for Microbiology, Washington, DC, USA.
8. Dollery CT. Intracellular drug concentrations. Clin Pharmacol Ther 2013; 93:263-6.
9. Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov 2006; 5:993-6.
10. Velkov T, Roberts KD, Nation RL et al. Teaching 'old' polymyxins new tricks: new-generation lipopeptides targeting Gram-negative 'superbugs'. ACS Chem Biol 2014; 9:1172-7.
11. Cardiff RD, Miller CH, Munn RJ. Manual hematoxylin and eosin staining of mouse tissue sections. Cold Spring Harb Protoc 2014; 2014:655-8.
12. Nation RL, Velkov T, Li J. Colistin and polymyxin B: peas in a pod, or chalk and cheese? Clin Infect Dis 2014; 59:88-94.
13. Li J, Milne RW, Nation RL et al. Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration. Antimicrob Agents Chemother 2003; 47:1766-70.
14. Li J, Milne RW, Nation RL et al. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J Antimicrob Chemother 2004; 53:837-40.
15. Azad MA, Finnin BA, Poudyal A et al. Polymyxin B induces apoptosis in kidney proximal tubular cells. Antimicrob Agents Chemother 2013; 57; 4329-35.
16. Dai C, Li J, Tang S et al. Colistin-induced nephrotoxicity in mice involves the mitochondrial, death receptor, and endoplasmic reticulum pathways. Antimicrob Agents Chemother 2014; 58:4075-85.